Effects of non-steroidal anti-inflammatory drugs on Aβ deposition in Aβ1-42 transgenic C. elegans

Brain Research

Volumn 1295, Issue , 2009, Pages 186-191

  Morita, Masahiko ^a   Osoda, Kazuhiko ^a   Yamazaki, Mayako ^a   Shirai, Fumiyuki ^a   Matsuoka, Nobuya ^a   Arakawa, Hiroyuki ^a   Nishimura, Shintaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

A transgenic C. elegans; Amyloid (A ); Ibuprofen; Naproxen; Non steroidal anti inflammatory drugs (NSAIDs); Thioflavin S

Indexed keywords

AMYLOID BETA PROTEIN; ARACHIDONIC ACID; IBUPROFEN; NAPROXEN; THIOFLAVINE;

ALZHEIMER DISEASE; ARTICLE; BACTERIAL STRAIN; CAENORHABDITIS ELEGANS; CELLULAR IMMUNITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG INHIBITION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

AMYLOID BETA-PROTEIN; ANALYSIS OF VARIANCE; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CAENORHABDITIS ELEGANS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; IBUPROFEN; INDOMETHACIN; MICROSCOPY, CONFOCAL; THIAZOLES;

CAENORHABDITIS ELEGANS;

EID: 70349253896     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.08.002     Document Type: Article

References (25)

1. Agdeppa E.D., Kepe V., Petric A., Satyamurthy N., Liu J., Huang S.C., Small G.W., Cole G.M., and Barrio J.R. In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl) (methyl)amino]-2-naphthyl]ethylidene) malononitrile. Neuroscience 117 (2003) 723-730
2. Eriksin J.L., Sagi S.A., Smith T.E., Weggen S., Das P., McLendon D.C., Ozols V.V., Jessing K.W., Zavitz K.H., Koo E.H., and Golde T.E. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. 112 (2003) 440-449
3. Fay D.S., Fluet A., Johnson C.J., and Link C.D. In vivo aggregation of β-amyloid peptide variants. J. Neurochem. 71 (1998) 1616-1625
4. Gutierrez-Zepeda A., and Luo Y. Testing the amyloid toxicity hypothesis of Alzheimer's disease in transgenic Caenorhabditis elegans model. Front. Biosci. 9 (2004) 3333-3338
5. Hodgkin J. Conventional genetics. In: Hope I.A. (Ed). C. elegans: a practical approach (1999), Oxford University Press, New York 245-270
6. Hirohata M., Ono K., Naiki H., and Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. Neuropharmacol. 49 (2005) 1088-1099
7. In't Veld B.A., Ruitenberg A., Hofman A., Launer L.J., van Duijn C.M., Stijnen T., Breteler M.M.B., and Stricker B.H.C. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. New Engl. Med. 345 (2001) 1515-1521
8. Iversen L.L., Mortishire-Smith R.J., Pollack S.J., and Shearman M.S. The toxicity in vitro of β-amyloid protein. Biochem. J. 311 (1995) 1-16
9. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., and Kliewer S.A. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 272 (1997) 3406-3410
10. Lim G.P., Yang F., Chu T., Chen T., Beech W., Teter B., Tran T., Ubeda O., Hsiao-Ashe K., Frautschy S.A., and Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20 (2000) 5709-5714
11. Lim G.P., Yang F., Chu T., Gahtan E., Ubeda O., Beech W., Overmier J.B., Hsiao-Ashe K., Frautschy S.A., and Cole G.M. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 22 (2001) 982-991
12. Link C.D. Expression of human β-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9368-9372
13. McGeer E.G., and McGeer P.L. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol. 33 (1998) 371-378
14. McGeer P.L. Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging 17 (2000) 1-11
15. Mello C.C., Kramer J.M., Stinchcomb D., and Ambros V. Efficient gene transfer in C. elegans: extrachromosomal maintenance and integration of transforming sequences. EMBO J. 10 (1991) 3959-3970
16. Morihara T., Chu T., Ubeda O., Beech W., and Cole G.M. Selective inhibition of Aβ42 production by NSAID R-enantiomers. J. Neurochem. 83 (2002) 1009-1012
17. Morley J.F., Brignull H.R., Weyers J.J., and Morimoto R.I. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10417-10422
18. Pignatello R., Pantò V., Salmaso S., Bersani S., Pistarà V., Kepe V., Barrio J.R., and Puglisi G. Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. Bioconjugate Chem. 19 (2008) 349-357
19. Selkoe D.J. The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8 (1998) 447-453
20. Simmons L.K., Patrick C.M., Tomaselli K.J., Rydel R.E., Fuson K.S., Brigham E.F., Wright S., Lieberburg I., Becker G.W., Brems D.N., and Li W.Y. Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro. Mol. Pharm. 45 (1994) 373-379
21. Stewart W.F., Kawas C., Corrada M., and Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 (1997) 626-632
22. Takada Y., Bhardwaj A., Potdar P., and Aggarwal B.B. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κ activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 23 (2004) 9247-9258
23. Takahashi Y., Hayashi I., Tominari Y., Rikumaru K., Morohashi Y., Kan T., Natsugari H., Fukuyama T., Tomita T., and Iwatsubo T. Sulindacsulfide is a noncompetitive γ-secretase inhibitor that preferentially reduces Aβ42 generation. J. Biol. Chem. 278 (2003) 18664-18670
24. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Bulter T., Kang D.E., Marquez-Sterling N., Golde T.E., and Koo E.H. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414 (2001) 212-216
25. Wu Y., Wu Z., Butko P., Christen Y., Lambert M.P., Klein W.L., Link C.D., and Luo Y. Amyloid-β-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and Ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 26 (2006) 13102-13113